FCF Yield

GSK’s free cash flow (FCF) yield of 4.7% means that for every $100 of its stock price, the company generates about $4.70 in free cash flow—cash left after operating and capital expenses.

This is above the healthcare sector median of 3.3%, placing GSK in the 74th percentile among its peers, indicating a relatively higher cash return compared to similar companies. However, the year-over-year and quarter-over-quarter changes, as well as the 8-quarter trend, are listed as N/A, so no direction can be inferred from the metric’s history. The combination of a yield above the sector median with no available trend data suggests the current valuation appears favorable based on cash generation, but the lack of past comparisons limits any assessment of improvement or deterioration. This metric generally supports the overall NEUTRAL verdict because the above-median yield is a positive signal, yet the absence of trend data and other factors likely keep the outlook balanced rather than bullish or bearish.

Frequently Asked Questions

Closest Sector Peers